0001562180-24-001226.txt : 20240209 0001562180-24-001226.hdr.sgml : 20240209 20240209174231 ACCESSION NUMBER: 0001562180-24-001226 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240207 FILED AS OF DATE: 20240209 DATE AS OF CHANGE: 20240209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Derakhshan Behrad CENTRAL INDEX KEY: 0001853109 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40236 FILM NUMBER: 24616405 MAIL ADDRESS: STREET 1: 3415 COLORADO AVE. CITY: BOULDER STATE: CO ZIP: 80303 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edgewise Therapeutics, Inc. CENTRAL INDEX KEY: 0001710072 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821725586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1715 38TH ST CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 720-262-7002 MAIL ADDRESS: STREET 1: 1715 38TH ST CITY: BOULDER STATE: CO ZIP: 80301 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-02-07 false 0001710072 Edgewise Therapeutics, Inc. EWTX 0001853109 Derakhshan Behrad C/O EDGEWISE THERAPEUTICS, INC. 1715 38TH STREET BOULDER CO 80301 false true false false Chief Business Officer true Common Stock 2024-02-07 4 M false 600.00 1.93 A 7620.00 D Common Stock 2024-02-07 4 S false 600.00 20.00 D 7020.00 D Common Stock 2024-02-08 4 M false 4600.00 1.93 A 11620.00 D Common Stock 2024-02-08 4 S false 4600.00 20.0106 D 7020.00 D Common Stock 2024-02-09 4 M false 4800.00 1.93 A 11820.00 D Common Stock 2024-02-09 4 S false 4800.00 20.0436 D 7020.00 D Stock Option (Right to Buy) 1.93 2024-02-07 4 M false 600.00 0.00 D 2030-12-15 Common Stock 600.00 154417.00 D Stock Option (Right to Buy) 1.93 2024-02-08 4 M false 4600.00 0.00 D 2030-12-15 Common Stock 4600.00 149817.00 D Stock Option (Right to Buy) 1.93 2024-02-09 4 M false 4800.00 0.00 D 2030-12-15 Common Stock 4800.00 145017.00 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 30, 2023. Includes 850 shares purchased on November 15, 2022, 1,304 shares purchased on May 15, 2023 and 1,608 shares purchased on November 15, 2023 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.135, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date. /s/ John R Moore Attorney-in-Fact for Behrad Derakhshan 2024-02-09